Large-scale processing of recombinant retroviruses for gene therapy
- PMID: 9933508
- DOI: 10.1021/bp980106m
Large-scale processing of recombinant retroviruses for gene therapy
Abstract
Gene therapy is a new therapeutic modality with the potential of treating inherited and acquired diseases. Several viral and physicochemical vehicles have been used for the transfer of genes to mammalian cells, but recombinant retroviruses are used in the majority of gene therapy clinical trials today. In this communication, we review the major concerns associated with the large-scale production and processing of retroviral particles. While some of the current processes for manufacturing recombinant proteins will be applicable to recombinant retroviruses, the instability, sensitivity to inhibitors, complexity, and size of retroviral particles require that new technologies be designed and evaluated. Here, we examine those issues critical to the design of strategies for production, concentration, and purification as well as formulation and storage of recombinant retroviruses. Processes for large-scale manufacturing of recombinant retroviruses that can produce high gene transfer efficiencies will have significant impact on the clinical implementation of gene therapy.
Similar articles
-
Amelioration of retrovirus-mediated gene transfer into hepatocellular carcinoma cells.Int J Oncol. 2001 Apr;18(4):801-7. Int J Oncol. 2001. PMID: 11251177
-
Purification of retrovirus particles using heparin affinity chromatography.Methods Mol Biol. 2008;434:1-11. doi: 10.1007/978-1-60327-248-3_1. Methods Mol Biol. 2008. PMID: 18470635
-
Downstream processing of oncoretroviral and lentiviral gene therapy vectors.Biotechnol Adv. 2006 May-Jun;24(3):321-37. doi: 10.1016/j.biotechadv.2005.12.001. Epub 2006 Jan 30. Biotechnol Adv. 2006. PMID: 16448798 Review.
-
Strategies for the isolation and purification of retroviral vectors for gene therapy.Bioseparation. 1996;6(4):211-28. Bioseparation. 1996. PMID: 9032984 Review.
-
Optimization of retroviral vector generation for clinical application.J Gene Med. 2001 Sep-Oct;3(5):427-36. doi: 10.1002/jgm.204. J Gene Med. 2001. PMID: 11601756
Cited by
-
Osmolytes in vaccine production, flocculation and storage: a critical review.Hum Vaccin Immunother. 2019;15(2):514-525. doi: 10.1080/21645515.2018.1526585. Epub 2018 Oct 12. Hum Vaccin Immunother. 2019. PMID: 30273503 Free PMC article. Review.
-
Viral vectors: from virology to transgene expression.Br J Pharmacol. 2009 May;157(2):153-65. doi: 10.1038/bjp.2008.349. Br J Pharmacol. 2009. PMID: 18776913 Free PMC article. Review.
-
Engineering Non-Human RNA Viruses for Cancer Therapy.Vaccines (Basel). 2023 Oct 20;11(10):1617. doi: 10.3390/vaccines11101617. Vaccines (Basel). 2023. PMID: 37897020 Free PMC article. Review.
-
Retroviral vectors produced in the cytoplasmic vaccinia virus system transduce intron-containing genes.J Virol. 2002 Feb;76(3):1236-43. doi: 10.1128/jvi.76.3.1236-1243.2002. J Virol. 2002. PMID: 11773399 Free PMC article.
-
Highly efficient concentration of lenti- and retroviral vector preparations by membrane adsorbers and ultrafiltration.BMC Biotechnol. 2011 May 20;11:55. doi: 10.1186/1472-6750-11-55. BMC Biotechnol. 2011. PMID: 21599966 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
